Dapansutrile

Product Description

Dapansutrile is a NLRP3 inflammasome inhibitor that disrupts inflammasome formation. Reduces LPS/ATP-induced IL-1β secretion in human and mouse macrophages in vitro, without affecting TNFα levels. Reduces LPS-induced inflammation in vivo. Also reduces joint swelling and markers of inflammation in synovial fluid in a mouse model of acute arthritis. Displays cardioprotective effects in a mouse model of cardiac ischemic reperfusion injury.

OLT1177® is a registered trademark of Olatec Therapeutics LLC in the United States and other countries.

Solubility

Preparing Stock Solutions for Dapansutrile

The following data is based on the product molecular weight 133.17

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	7.51 mL	37.55 mL	75.09 mL
5 mM	1.50 mL	7.51 mL	15.02 mL
10 mM	0.75 mL	3.75 mL	7.51 mL
50 mM	0.15 mL	0.75 mL	1.50 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Marchetti NLRP3 inflammasome inhibitor OLT1177® suppresses joint inflammation in murine models of acute arthritis. Arthritis Res.Ther. 2018 PMID: 30075804
• Toldo The NLRP3 inflammasome inhibitor, OLT1177® (Dapansutrile), reduces infarct size and preserves contractile function after ischemia reperfusion injury in the mouse. J.Cardiovasc.Pharmacol. 2019 PMID: 30747785
• Marchetti OLT1177®, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc.Natl.Acad.Sci.USA. 2018 PMID: 29378952